Naphthazarin enhances ionizing radiation-induced cell cycle arrest and apoptosis in human breast cancer cells

International Journal of Oncology

Volumn 46, Issue 4, 2015, Pages 1659-1666

  Kim, Min Young ^a,b   Park, Seong Joon ^a,b   Shim, Jae Woong ^a   Yang, Kwangmo ^a,c,d   Kang, Ho Sung ^b   Heo, Kyu ^a  

^a Dongnam Institute of Radiological and Medical Sciences   (South Korea)

^b Pusan National University   (South Korea)

^c Dongnam Institute of Radiological and Medical Science   (South Korea)

^d Korea Institute of Radiation and Medical Science   (South Korea)

Author keywords

Apoptosis; Cell cycle arrest; Ionizing radiation; Naphthazarin

Indexed keywords

DNA METHYLTRANSFERASE 1; HISTONE DEACETYLASE 1; NAPHTHAZARIN; PROTEIN P21; PROTEIN P53; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; NAPHTHOQUINONE; RADIOSENSITIZING AGENT;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL INTERACTION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IONIZING RADIATION; MCF 7 CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; BREAST NEOPLASMS; CELL CYCLE CHECKPOINT; CHEMORADIOTHERAPY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PROCEDURES; RADIATION RESPONSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CHEMORADIOTHERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; NAPHTHOQUINONES; PROMOTER REGIONS, GENETIC; RADIATION-SENSITIZING AGENTS;

EID: 84923070783     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2857     Document Type: Article

References (40)

1. JEMAL A, BRAY F, CENTER MM, FERLAY J, WARD E and FORMAN D: Global Cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. BOZOVIC-SPASOJEVIC I, AZAMBUJA E, MCCASKILL-STEVENS W, DINH P and CARDOSO F: Chemoprevention for breast cancer. Cancer Treat Rev 38: 329-339, 2012.
3. ZHANG Y, LUO M, ZU Y, et al: Dryofragin, a phloroglucinol derivative, induces apoptosis in human breast Cancer MCF-7 cells through RoS-mediated mitochondrial pathway. Chem Biol Interact 199: 129-136, 2012.
4. KRIFA M, PIZZI A, MOUSLI M, CHEKIR-GHEDIRA L, LELOUP L and GHEDIRA K: Limoniastrum guyonianum aqueous gall extract induces apoptosis in colorectal Cancer cells by inhibiting calpain activity. Tumour Biol 35: 7877-7885, 2014.
5. ZIECH D, ANESTOPOULOS I, HANAF R, et al: Pleiotrophic effects of natural products in RoS-induced carcinogenesis: The role of plant-derived natural products in Oral Cancer chemoprevention. Cancer Lett 327: 16-25, 2012.
6. MAGEE PJ, OWUSU-APENTEN R, MCCANN MJ, GILL CI and ROWLAND IR: Chickpea (Cicer arietinum) and other plant-derived protease inhibitor concentrates inhibit breast and prostate Cancer Cell proliferation in vitro. Nutr Cancer 64: 741-748, 2012.
7. FANG Y, DEMARCO VG and NICHOLL MB: Resveratrol enhances radiation sensitivity in prostate Cancer by inhibiting Cell proliferation and promoting Cell senescence and apoptosis. Cancer Sci 103: 1090-1098, 2012.
8. WANG Q, FAN H, LIU Y, et al: Curcumin enhances the radio-sensitivity in nasopharyngeal carcinoma cells involving the reversal of differentially expressed long non-coding RNAs. Int J Oncol 44: 858-864, 2014.
9. CRAGG GM and NEWMAN DJ: Plants as a source of anti-cancer agents. J ethnopharmacol 100: 72-79, 2005.
10. SRIVASTAVA V, NEGI AS, KUMAR JK, GUPTA MM and KHANUJA SP: Plant-based Anticancer molecules: A chemical and biological profile of some important leads. Bioorg Med Chem 13: 5892-5908, 2005.
11. KOUROUNAKIS A P, ASSIMOPOULOU AN, PAPAGEORGIOU VP, GAVALAS A and KOUROUNAKIS PN: Alkannin and shikonin: Effect on free radical processes and on infammation-a preliminary pharmacochemical investigation. Arch Pharm (Weinheim) 335: 262-266, 2002.
12. ACHARYA BR, BHATTACHARYYA S, CHOUDHURY D and CHAKRABARTI G: The microtubule depolymerizing agent naphthazarin induces both apoptosis and autophagy in A549 lung Cancer cells. Apoptosis 16: 924-939, 2011.
13. KUNDAKOVIC T, STANOJKOVIC T, JURANIC Z and KOVACEVIC N: Cytotoxicity in vitro of naphthazarin derivatives from onosma arenaria. Phytother Res 20: 602-604, 2006.
14. JOHANSSON AC, NORBERG-SPAAK L and ROBERG K: Role of lysosomal cathepsins in naphthazarin-and fas-induced apoptosis in Oral squamous Cell carcinoma cells. Acta otolaryngol 126: 70-81, 2006.
15. SONG GY, KIM Y, YOU YJ, CHO H, KIM SH, SOK DE and AHN BZ: Naphthazarin derivatives (VI): Synthesis, inhibitory effect on DNA topoisomerase-I and antiproliferative activity of 2-or 6-(1-oxyiminoalkyl)-5, 8-dimethoxy-1, 4-naphthoquinones. Arch Pharm (Weinheim) 333: 87-92, 2000.
16. KIM JA, LEE EK, PARK SJ, KIM ND, HYUN DH, LEE CG, LEE JH, YANG KM, HEO K and SON TG: Novel anti-cancer role of naph-thazarin in human gastric Cancer cells. Int J Oncol 40: 157-162, 2012.
17. SHERR CJ and ROBERTS JM: CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999.
18. LIM S and KALDIS P: Cdks, cyclins and CKIs: Roles beyond Cell cycle regulation. Development 140: 3079-3093, 2013.
19. LEE YH and BAE YS: Phospholipase D2 downregulation induces cellular senescence through a reactive oxygen species-p53-p21Cip1/WAF1 pathway. FEBS Lett 588: 3251-3258, 2014.
20. Saha K, Adhikary G, Kanade SR, Rorke EA and Eckert RL: P38δ regulates p53 to control p21Cip1 expression in human epidermal keratinocytes. J Biol Chem 289: 11443-11453, 2014.
21. YADAV V, SULTANA S, YADAV J and SAINI N: Gatifoxacin induces S and G2-phase Cell cycle arrest in pancreatic Cancer cells via p21/p27/p53. PLoS one 7: E47796, 2012.
22. KHAN M, RASUL A, YI F, ZHONG L and MA T: Jaceosidin induces p53-dependent G2/M phase arrest in U87 glioblastoma cells. Asian Pac J Cancer Prev 12: 3235-3238, 2011.
23. POWELL BL, VAN STAVEREN IL, ROOSKEN P, GRIEU F, BERNS EM and IACOPETTA B: Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis 23: 311-315, 2002.
24. DARCY KM, BRADY WE, MCBROOM JW, et al: Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic oncology Group study. Gynecol Oncol 111: 487-495, 2008.
25. UNOKI M, NISHIDATE T and NAKAMURA Y: ICBP90, an e2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 23: 7601-7610, 2004.
26. BOSTICK M, KIM JK, ESTÈVE PO, CLARK A, PRADHAN S and JACOBSEN SE: UHRF1 plays a role in maintaining DNA meth-ylation in mammalian cells. Science 317: 1760-1764, 2007.
27. ACHOUR M, JACQ X, RONDÉ P, et al: The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VeGF Gene expression. Oncogene 27: 2187-2197, 2008.
28. ACHOUR M, FUHRMANN G, ALHOSIN M, et al: UHRF1 recruits the histone acetyltransferase Tip60 and controls its expression and activity. Biochem Biophys Res Commun 390: 523-528, 2009.
29. ALHOSIN M, SHARIF T, MOUSLI M, ETIENNE-SELLOUM N, FUHRMANN G, SCHINI-KERTH VB and BRONNER C: Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties. J Exp Clin Cancer Res 30: 41, 2011.
30. BRONNER C, ACHOUR M, ARIMA Y, CHATAIGNEAU T, SAYA H and SCHINI-KERTH VB: The UHRF family: Oncogenes that are drugable targets for Cancer therapy in the near future. Pharmacol Ther 115: 419-434, 2007.
31. UNOKI M, BRUNET J and MOUSLI M: Drug discovery targeting epigenetic codes: The great potential of UHRF1, which links DNA methylation and histone modifcations, as a drug target in cancers and toxoplasmosis. Biochem Pharmacol 78: 1279-1288, 2009.
32. KIM JK, ESTÈVE PO, JACOBSEN SE and PRADHAN S: UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cells. Nucleic Acids Res 37: 493-505, 2009.
33. YAMAGUCHI T, CUBIZOLLES F, ZHANG Y, REICHERT N, KOHLER H, SEISER C and MATTHIAS P: Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev 24: 455-469, 2010.
34. SALDANHA SN, KALA R and TOLLEFSBOL TO: Molecular mechanisms for inhibition of colon Cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate. Exp Cell Res 324: 40-53, 2014.
35. TIEN AL, SENBANERJEE S, KULKARNI A, et al: UHRF1 depletion causes a G2/M arrest, activation of DNA damage response and apoptosis. Biochem J 435: 175-185, 2011.
36. VIJAYA RAG HAVALU S, DER MAWA NJK, CHERIYAT HV and LABHASETWA RV: Highly synergistic effect of sequential treatment with epigenetic and Anticancer drugs to overcome drug resistance in breast Cancer cells is mediated via activation of p21 Gene expression leading to G2/M cycle arrest. Mol Pharm 10: 337-352, 2013.
37. ZHANG X, LI X, ZHANG N, YANG Q and MORAN MS: Low doses ionizing radiation enhances the invasiveness of breast Cancer cells by inducing epithelial-mesenchymal transition. Biochem Biophys Res Commun 412: 188-192, 2011.
38. Tsai JH, Hsu LS, Lin CL, Hong HM, Pan MH, Way TD and Chen WJ: 3, 5, 4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast Cancer Cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition. Toxicol Appl Pharmacol 272: 746-756, 2013.
39. LUO H, WANG L, SCHULTE BA, YANG A, TANG S and WANG GY: Resveratrol enhances ionizing radiation-induced premature senescence in lung Cancer cells. Int J Oncol 43: 1999-2006, 2013.
40. HALL EJ and WUU CS: Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56: 83-88, 2003.